Mesoblast Limited (NASDAQ:MESO – Get Rating) has been assigned an average rating of “Hold” from the six brokerages that are currently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $10.13.
Several equities research analysts have commented on the company. StockNews.com assumed coverage on Mesoblast in a report on Thursday, May 18th. They issued a “sell” rating on the stock. William Blair assumed coverage on Mesoblast in a report on Thursday, March 9th. They issued an “outperform” rating and a $8.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $23.00 target price on shares of Mesoblast in a report on Wednesday, February 1st. Finally, Chardan Capital reissued a “sell” rating and issued a $2.50 target price on shares of Mesoblast in a report on Wednesday, March 1st.
Mesoblast Trading Down 1.1 %
NASDAQ MESO opened at $3.45 on Tuesday. The company has a quick ratio of 1.43, a current ratio of 1.43 and a debt-to-equity ratio of 0.19. Mesoblast has a twelve month low of $2.14 and a twelve month high of $4.35. The firm has a market capitalization of $561.80 million, a PE ratio of -5.56 and a beta of 3.27. The stock’s 50 day moving average is $3.37 and its 200 day moving average is $3.30.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of MESO. State Street Corp purchased a new position in shares of Mesoblast in the first quarter worth $757,000. Ronit Capital LLP purchased a new position in shares of Mesoblast in the third quarter worth $382,000. BlackRock Inc. raised its stake in shares of Mesoblast by 20.8% in the first quarter. BlackRock Inc. now owns 864,638 shares of the company’s stock worth $3,649,000 after purchasing an additional 149,023 shares during the last quarter. Millennium Management LLC purchased a new position in shares of Mesoblast in the fourth quarter worth $344,000. Finally, Jane Street Group LLC purchased a new stake in Mesoblast during the fourth quarter valued at $187,000. Hedge funds and other institutional investors own 2.60% of the company’s stock.
Mesoblast Company Profile
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases.
- Get a free copy of the StockNews.com research report on Mesoblast (MESO)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.